-
Microlipophagy and Radioresistance in SCLC
2026-09-11
A 2026 study links microlipophagy-driven lipid-droplet remodeling with radioresistant phenotypes in small-cell lung cancer. Its integrated imaging, lipid profiling, pharmacological inhibition, and transcriptomic design suggests that autophagy-dependent metabolic adaptation may be a tractable research target, while also highlighting important limits to causal interpretation.
-
In Vitro Drug Response Metrics in Cancer
2026-09-11
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent dimensions of anticancer response. Its central practical implication is that drug screens should separate proliferative arrest from death and account for their different timing rather than treating one viability value as a complete response profile.
-
Griseofulvin Workflows for Microtubule Assays
2026-09-10
Griseofulvin provides a practical perturbation tool for connecting microtubule disruption with fungal cell mitosis inhibition. This guide combines DMSO handling, time-resolved phenotyping, flow-cytometric mechanism tests, and troubleshooting strategies for reproducible antifungal drug research.
-
Sulfaphenazole: CYP2C9 Inhibitor Workflows
2026-09-10
Sulfaphenazole is a practical probe for CYP2C9-mediated drug metabolism modulation, oxidative stress, and vascular recovery studies. This workflow-focused guide connects enzyme inhibition assays with preclinical perfusion, wound-healing, and antibacterial applications while separating established evidence from experimental starting conditions.
-
NSC 87877: A Mechanistic Guide to Shp2 Inhibition
2026-09-09
NSC 87877 is a Shp2 inhibitor for dissecting phosphatase-dependent signaling in neuroinflammation, cancer, and pain models. This guide connects its biochemical profile with the Nespas/miR-383-3p/SHP2 findings reported after ischemic stroke and translates them into better assay decisions.
-
Sulfaphenazole: From CYP2C9 Tool to Translational Strategy
2026-09-09
Sulfaphenazole is more than a conventional enzyme inhibitor: it is a mechanistically useful bridge between cytochrome P450 biology, antibacterial discovery, vascular endothelial function research, and translational assay design. This article examines how to use its CYP2C9 activity rigorously, interpret its antimycobacterial potential, and position it against optimized sulfonamide derivatives.
-
Hyaluronic Acid Sodium Salt for siRNA Nanoparticles
2026-09-08
Hyaluronic acid sodium salt links extracellular-matrix biology with practical siRNA nanoparticle design, from coating screens to organoid validation. This guide translates a recent TDRD9-targeting lung injury study into reproducible material-handling, assay-selection, and troubleshooting strategies.
-
740 Y-P: Practical PI3K Activation Protocol
2026-09-07
740 Y-P (SKU B5246) is a cell-permeable PI 3-kinase activator for controlled modulation of PI3K/AKT signaling in biochemical and cellular workflows. This guide covers formulation, assay setup, and quality controls, while limiting interpretation to research use because the supplied dossier does not establish in vivo, clinical, or broadly transferable conditions.
-
Lactate Workflows for Metabolic–Immune Research
2026-09-07
Lactate can serve as both a quantitative readout of glycolytic activity and a controlled metabolic signal in cell, hypoxia, mitochondrial, and tumor–immune models. This practical guide connects L-lactate handling with mechanistic assays of the NAT1–ENO1–TRAF6–PD-L1 pathway while emphasizing pH control, compartment-aware sampling, and reproducible normalization.
-
Dorsomorphin 2HCl for AMPK Causality
2026-09-05
Dorsomorphin 2HCl helps distinguish AMPK association from AMPK-dependent protection in metabolic assays, while also enabling BMP and iron-homeostasis studies. This workflow translates a recent probiotic–liver study into practical formulation, control, timing, and troubleshooting decisions.
-
Mono-ADP-Ribosylation Marks PARP7 and AHR for Degradation
2026-09-04
The reference study shows that blocking ubiquitylation or proteasomal turnover exposes endogenous ADP-ribosylated proteins that are otherwise rapidly degraded. It identifies DTX2 as the E3 ligase controlling degradation of ADP-ribosylated PARP7, AHR, and related substrates, establishing mono-ADP-ribosylation as a physiologically relevant degradation signal.
-
Nicotine Signaling in Chronic Kidney Disease
2026-09-04
This review synthesizes clinical and experimental evidence that nicotine contributes to chronic kidney disease progression through non-neuronal nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and pro-fibrotic signaling. Its principal contribution is a mechanistic framework linking smoking-associated renal deterioration to nicotine biology while distinguishing nicotine effects from the broader chemical complexity of cigarette smoke.
-
PA-824: From Nitro-Reduction to TB Assay Design
2026-09-04
PA-824 is a bicyclic nitroimidazole derivative whose activity links mycolic-acid disruption with respiratory collapse in Mycobacterium tuberculosis. This article explains how that biology should shape phenotype-aware assays, combination studies, and interpretation of drug-tolerant populations.
-
v-Agatoxin-IVA and N-Type Ca Channel Selectivity
2026-09-03
Sidach and Mintz showed that v-Agatoxin-IVA, widely used as a high-selectivity P-type calcium channel probe, can also produce incomplete, low-affinity blockade of neuronal N-type currents. The work demonstrates why toxin concentration, channel gating, and cellular context must be considered when assigning pharmacological channel identities.
-
Engineering a Focused Bitespiramycin Producer
2026-09-02
The reference study used an in-frame partial deletion of the sspA 3-O-acyltransferase gene to redirect a complex bitespiramycin biosynthetic profile toward 400-isovalerylspiramycin I. Its strain-engineering strategy illustrates how targeted tailoring-enzyme disruption can simplify antibiotic composition and improve the interpretability of downstream production and susceptibility studies.